Advertisement

Possible Role of Opioids in Mental Disorders

Present State of Knowledge
  • H. M. Emrich

Abstract

The discovery of endorphinergic systems (for a review see Herz, 1978; Snyder, 1978) initiated a new field of research in biological psychiatry, the importance of which is, as yet, incompletely assessible. There are, however, some indications of the importance of opioid peptides in stress phenomena, in affective disorders, and, possibly, in schizophrenic psychoses. The aim of this chapter is to evaluate the present state of knowledge in this field.

Keywords

Affective Disorder Schizophrenic Patient Opioid Peptide Opiate Receptor Neuroleptic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angst, J., Autenrieth, V., Brem, F., Koukkou, M., Meyer, H., Stassen, H. H., and Storck, U., 1979, Preliminary results of treatment with β-endorphin in depression, in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney Jr., and N. S. Kline, eds.), pp. 518–528, MacMillan Press, London.Google Scholar
  2. Berger, P. A., Watson, S. J., Akil, H., and Barchas, J. D., 1979, Naloxone administration in chronic hallucinating schizophrenic patients, in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney Jr., and N. S. Kline, eds.), pp. 423–434, MacMillan Press, London.Google Scholar
  3. Bourgeois, M., Laforge, E., Muyard, J., Blayac, J., and Lemoine, J., 1980, Endorphines et schizophrénies. II. Les essais de traitement des schizophrénies par la Des-tyr-γ-endorphine (DT7E) (dont un essai personnel), Ann. J. Med. Psychiatr. 138:1112.Google Scholar
  4. Byck, R., 1976, Peptide transmitters: A unifying hypothesis for euphoria, respiration, sleep, and the action of lithium, Lancet II:72.CrossRefGoogle Scholar
  5. Casey, D. E., Korsgaard, S., Gerlach, J., Jorgensen, A., and Simmelsgaard, H., 1981, Effect of des-tyrosine-γ-endorphin in tardive dyskinesia, Arch. Gen. Psychiatry 38:158.PubMedCrossRefGoogle Scholar
  6. Davis, G. C., Bunney, W. E., Jr., De Fraites, E. G., Kleinman, J. E., van Kammen, D. P., Post, R. M., and Wyatt, R. J., 1977, Intravenous naloxone administration in schizophrenia and affective illness, Science 197:1 A.CrossRefGoogle Scholar
  7. Davis, G. C., Bunney, W. E., Jr., Buchsbaum, M. S., De Fraites, E. G., Duncan, W., Gillin, J. C., van Kammen, D. P., Kleinman, J., Murphy, D. L., Post, R. M., Reus, V., and Wyatt, R. J., 1979, Use of narcotic antagonists to study the role of endorphins in normal and psychiatric patients, in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney Jr., and N. S. Kline, eds.), pp. 393–406, MacMillan Press, London.Google Scholar
  8. Davis, G. C., Extein, I., Reus, V. I., Hamilton, W., Post, R. M., Goodwin, F. K., and Bunney, W. E., Jr., 1980, Failure of naloxone to reduce manic symptoms, Am. J. Psychiatry 137:1583.PubMedGoogle Scholar
  9. de Wied, D., 1979, Schizophrenia as an inborn error in the degradation of β-endorphin—A hypothesis, Trends Neurosci. 2:79.CrossRefGoogle Scholar
  10. de Wied, D., Kovács, G. L., Bohus, B., van Ree, J. M., and Greven, H. M., 1978, Neuroleptic activity of the neuropeptide β-LPH62–77 ([des-Tyr1]-γ-endorphin; DT7E), Eur. J. Pharmacol. 49:427.PubMedCrossRefGoogle Scholar
  11. Deyo, S. N., Swift, R. M., and Miller, R. J., 1979, Morphine and endorphins modulate dopamine turnover in rat median eminence, Proc. Natl. Acad. Sci. USA 76:3006.PubMedCrossRefGoogle Scholar
  12. Dole, V. P., and Nyswander, M. E., 1967, Heroin addiction—A metabolic disease, Arch. Intern. Med. 120:19.PubMedCrossRefGoogle Scholar
  13. Emrich, H. M., 1978, Ueber eine moegliche Rolle von Endorphinen bei psychischen Krankheiten, Arzneim. Forsch. 28:1270.Google Scholar
  14. Emrich, H. M. (ed.), 1981, The Role of Endorphins in Neuropsychiatry, Karger, Basel.Google Scholar
  15. Emrich, H. M., 1982a, A possible role of opioid substances in depression, in: Typical and Atypical Antidepressants, Vol. 1, Molecular Mechanisms (E. Costa and G. Racagni, eds.), pp. 77–84 Raven Press, New York.Google Scholar
  16. Emrich, H. M., 1982b, A possible role of endorphinergic systems in schizophrenia, in: Psycho-biology of Schizophrenia (M. Namba and H. Kaiya, eds.), pp. 291–297. Pergamon Press, Elmsford, N.Y.Google Scholar
  17. Emrich, H. M., Cording, C., Pirée, S., Kölling, A., von Zerssen, D., and Herz, A., 1977, Indication of an antipsychotic action of the opiate antagonist naloxone, Pharmakopsychiatr. Neuro-Psychopharmakol. 10:265.Google Scholar
  18. Emrich, H. M., Höllt, V., Kissling, W., Fischler, M., Laspe, H., Heinemann, H., von Zerssen, D., and Herz, A., 1979a, β-Endorphin-like immunoreactivity in cerebrospinal fluid and plasma of patients with schizophrenia and other neuropsychiatric disorders, Pharmakopsychiatr. Neuro-Psychopharmakol. 12:269.Google Scholar
  19. Emrich, H. M., Höllt, V., Laspe, H., Fischler, M., Heinemann, H., Kissling, W., von Zerssen, D., and Herz, A., 1979b, Studies on a possible pathological significance of endorphins in psychiatric disorders, in: Neuropsychopharmacology (B. Saletu, P. Berner, and L. Hollister, eds.), pp. 527–534, Pergamon Press, Elmsford, N.Y.Google Scholar
  20. Emrich, H. M., Cording, C., Pirée, S., Kölling, A., Möller, H.-J., von Zerssen, D., and Herz, A., 1979c, Actions of naloxone in different types of psychoses, in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney Jr., and N. S. Kline, eds.), pp. 452–460, MacMillan Press, London.Google Scholar
  21. Emrich, H. M., Möller, H.-J., Laspe, H., Meisel-Kosik, I., Dwinger, H., Oechsner, R., Kissling, W., and von Zerssen, D., 1979d, On a possible role of endorphins in psychiatric disorders: Actions of naloxone in psychiatric patients in: Biological Psychiatry Today (J. Obiols, C. Ballús, E. Gonzáles Monclús, and J. Pujol, eds.), pp. 798–805, Elsevier/North-Holland, Amsterdam.Google Scholar
  22. Emrich, H. M., Höllt, V., Bergmann, M., Kissling, W., Schmid, W., von Zerssen, D., and Herz, A., 1980a, Plasma levels of β-endorphin under chronic neuroleptic treatment in schizophrenic patients: Failure of naloxone to counteract curative effects of neuroleptic drugs, in: Neural Peptides and Neuronal Communication (E. Costa and M. Trabucchi, eds.), pp. 489–502, Raven Press, New York.Google Scholar
  23. Emrich, H. M., Zaudig, M., Kissling, W., Dirlich, G., von Zerssen, D., and Herz, A., 1980b, Des-tyrosyl-γ-endorphin in schizophrenia: A double-blind trial in 13 patients, Pharmakopsychiatr. Neuro-Psychopharmakol. 13:290.Google Scholar
  24. Emrich, H. M., Zaudig, M., von Zerssen, D., Herz, A., and Kissling, W., 1980c, Des-tyr-γ-en-dorphin in schizophrenia, Lancet II:1364.CrossRefGoogle Scholar
  25. Emrich, H. M., Vogt, P., and Herz, A., 1981a, A possible role of opioids in depression: Significant improvement after buprenorphine, in: Biological Psychiatry 1981 (C. Perris, G. Struwe, and B. Jansson, eds.), pp. 380–385, Elsevier/North-Holland, Amsterdam.Google Scholar
  26. Emrich, H. M., Zaudig, M., von Zerssen, D., Kissling, W., Dirlich, G., and Herz, A., 1981b, Action of (des-Tyr1)-γ-endorphin in schizophrenia, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 279–286, Karger, Basel.Google Scholar
  27. Extein, I., Lo, C., Goodwin, F., and Schoenfeld, R. I., 1979, Dopamine-mediated behavior produced by the enkephalin analogue FK 33–824, Psychiatry Res. 1:333.PubMedCrossRefGoogle Scholar
  28. Extein, I., Pickar, D., Gold, M. S., Gold, P. W., Pottash, A. L. C., Sweeney, D. R., Ross, R. J., Rebard, R., Martin, D., and Goodwin, F. K., 1981, Methadone and morphine in depression, Psychopharmacol. Bull. 17:29.PubMedGoogle Scholar
  29. Faden, A. I., and Holaday, J. W., 1979, Opiate antagonists: A role in the treatment of hypovolemic shock, Science 205:317.PubMedCrossRefGoogle Scholar
  30. Faden, A. I., and Holaday, J. W., 1981, Endorphins in traumatic spinal injury: Pathophysiological studies and clinical implications, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 158–174, Karger, Basel.Google Scholar
  31. Ferland, L., Fuxe, K., Eneroth, P., Gustafsson, J.-A., and Skett, P., 1977, Effects of methionine-enkephalin on prolactin release and catecholamine levels and turnover in the median eminence, Eur. J. Pharmacol. 43:89.PubMedCrossRefGoogle Scholar
  32. Fink, M., Simeon, J., Itil, T. M., and Freedman, A. M., 1970, Clinical antidepressant activity of cyclazocine—a narcotic antagonist, Clin. Pharmacol. Ther. 11:41.PubMedGoogle Scholar
  33. Gemer, R. H., Catlin, D. H., Gorelick, D. A., Hui, K. K., and Li, C. H., 1980, β-Endorphin: Intravenous infusion causes behavioral change in psychiatric inpatients, Arch. Gen. Psychiatry Google Scholar
  34. Goldstein, A., 1976, Opioid peptides (endorphins) in pituitary and brain, Science 193:1081.PubMedCrossRefGoogle Scholar
  35. Gorelick, D. A., Catlin, D. H., and Gemer, R. H., 1981, β-Endorphin studies in psychiatric patients, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 236–245, Karger, Basel.Google Scholar
  36. Grevert, P., and Goldstein, A., 1978, Endorphins: Naloxone fails to alter experimental pain or mood in humans, Science 199:1093.PubMedCrossRefGoogle Scholar
  37. Gunne, L. M., Lindström, L., and Terenius, L., 1977, Naloxone-induced reversal of schizophrenic hallucinations, J. Neural Transm. 40:13.PubMedCrossRefGoogle Scholar
  38. Herz, A. (ed.), 1978, Developments in Opiate Research, Dekker, New York.Google Scholar
  39. Herz, A., 1981, On the role of endorphins in addiction, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 175–180, Karger, Basel.Google Scholar
  40. Holaday, J. W., and Faden, A. I., 1978, Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock, Nature (London) 275:450.CrossRefGoogle Scholar
  41. Holaday, J. W., Tortella, F. C., and Belenky, G. L., 1981, Electroconvulsive shock (ECS) results in a functional activation of endorphin systems, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 142–157, Karger, Basel.Google Scholar
  42. Hollister, L. E., Johnson, K., Boukhabza, D., and Gillespie, H. K., 1981, Aversive effects of naltrexone in subjects not dependent on opiates Drug Alcohol Depend. 7:1.CrossRefGoogle Scholar
  43. Höllt, V., 1981, Effects of neuroleptic drugs on endogenous peptides in the rat, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 1–18, Karger, Basel.Google Scholar
  44. Höllt, V., and Bergmann, M., 1982, Effect of acute and chronic haloperidol treatment on the concentrations of immunoreactive β-endorphin in plasma, pituitary and brain of rats, Neuropharmacology 21:147.PubMedCrossRefGoogle Scholar
  45. Höllt, V., Emrich, H. M., Müller, O. A., and Fahlbusch, R., 1978a, β-Endorphin-like immuno-reactivity (β-ELI) in human plasma and cerebrospinal fluid (CSF), in: Characteristics and Function of Opioids (J. M. van Ree and L. Terenius, eds.), pp. 279–280, Elsevier/North-Holland, Amsterdam.Google Scholar
  46. Höllt, V., Przewlocki, R., and Herz, A., 1978b, Radioimmunoassay of β-endorphin: Basal and stimulated levels in extracted rat plasma, Naunyn-Schmiedebergs Arch. Pharmacol. 303:171.PubMedCrossRefGoogle Scholar
  47. Höllt, V., Przewlocki, R., and Herz, A., 1978c, β-Endorphin-like immunoreactivity in plasma, pituitaries and hypothalamus of rats following treatment with opiates, Life Sci. 23:1057.PubMedCrossRefGoogle Scholar
  48. Höllt, V., Hillebrand, G., Schmidt, B., and Gurland, H.-J., 1979, Endorphins in schizophrenia: Hemodialysis/hemoperfusion are ineffective in clearing β-Leu5-endorphin and β-endorphin from human plasma, Pharmakopsychiatr. Neuro-Psychopharmakol. 12:399.Google Scholar
  49. Höllt, V., Haarmann, I., Przewlocki, R., and Jerlicz, M., 1980, Long-term treatment of rats with morphine decreases in vitro biosynthesis in and release of ß-endorphin from intermediate/posterior lobes of pituitary, in: Neural Peptides and Neuronal Communication (E. Costa and M. Trabucchi, eds.), pp. 399–405, Raven Press, New York.Google Scholar
  50. Höllt, V., Emrich, H. M., Bergmann, M., Nedopil, N., Dieterle, D., Gurland, H.-J., Nusselt, L., von Zerssen, D., and Herz, A., 1982, ß-Endorphin-like immunoreactivity in CSF and plasma of neuropsychiatric patients, in: Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications (N. S. Shah and A. G. Donald, eds.), pp. 231–243, Plenum Press, New York.CrossRefGoogle Scholar
  51. Hong, J. S., Yang, H. Y. T., Gillin, J. C., Di Giulio, A. M., Fratta, W., and Costa, E., 1979, Chronic treatment with haloperidol accelerates the biosynthesis of enkephalins in rat striatum, Brain Res. 160:192.PubMedCrossRefGoogle Scholar
  52. Hosobuchi, Y., 1981, Periaqueductal gray stimulation in humans produces analgesia accompanied by elevation of β-endorphin and ACTH in ventricular CSF, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 109–122, Karger, Basel.Google Scholar
  53. Janowsky, D. S., Segal, D. S., Bloom, F., Abrams, A., and Guillemin, R., 1977, Lack of effect of naloxone on schizophrenic symptoms, Am. J. Psychiatry 134:926.PubMedGoogle Scholar
  54. Jasinski, D. R., Martin, W. R., and Haertzen, C. A., 1967, The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone), J. Pharmacol. Exp. Ther. 157:420.PubMedGoogle Scholar
  55. Kline, N. S., Li, C. H., Lehmann, H. E., Lajtha, A., Laski, E., and Cooper, T., 1977, β-Endorphin-induced changes in schizophrenic and depressed patients, Arch. Gen. Psychiatry 34:1111.PubMedCrossRefGoogle Scholar
  56. Kraepelin, E., 1901, Einfuehrung in die Psychiatrische Klinik, pp. 11, Joh. Ambrosius Barth-Verlag, Leipzig.Google Scholar
  57. Kraepelin, E., 1927, Psychiatrie I, pp. 817–819, Joh. Ambrosius Barth-Verlag, Leipzig.Google Scholar
  58. Kurland, A. A., McCabe, O. L., Hanlon, T. E., and Sullivan, D., 1977, The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride, Am. J. Psychiatry 134:1408.PubMedGoogle Scholar
  59. Lewis, R. V., Gerber, L. D., Stein, S., Stephen, R. L., Grosser, B. I., Velick, S. F., and Udenfriend, S., 1979, On βH-Leu5-endorphin and schizophrenia, Arch. Gen. Psychiatry 36:237.PubMedCrossRefGoogle Scholar
  60. Lindström, L. H., Widerlöv, E., Gunne, L. M., Wahlström, A., and Terenius, L., 1978, Endorphins in human cerebrospinal fluid: Clinical correlations to some psychotic states, Acta Psychiatr. Scand. 57:153.PubMedCrossRefGoogle Scholar
  61. Mackenzie, A. I., 1979, Naloxone in alcohol intoxication, Lancet I:733.CrossRefGoogle Scholar
  62. Manchanda, R., and Hirsch, S. R., 1981, (Des-Tyr1]-γ-endorphin in the treatment of schizophrenia, Psychol. Med. 11:401.PubMedCrossRefGoogle Scholar
  63. Martin, W. R. (ed.), 1977, Drug addiction. I. Morphine, Sedative-Hypnotic and Alcohol Dependence, Handbuch der experimentellen Pharmakologie, Vol. 45, Springer, Berlin.Google Scholar
  64. Mayer, D. J., and Watkins, L. R., 1981, Role of endorphins in endogenous pain control systems, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 68–96 Karger, Basel.Google Scholar
  65. Mayer, D. J., Price, D. D., and Rafii, A., 1977, Antagonism of acupuncture analgesia in man by the narcotic antagonist naloxone, Brain Res. 121:368.PubMedCrossRefGoogle Scholar
  66. Millan, M. J., 1981, Stress and endogenous opioid peptides: A review, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 49–67, Karger, Basel.Google Scholar
  67. Millan, M. J., and Duka, Th., 1981, Anxiolytic properties of opiates and endogenous opioid peptides and their relationship to the actions of benzodiazepines, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 123–141, Karger, Basel.Google Scholar
  68. Millan, M. J., and Emrich, H. M., 1981, Endorphinergic systems and the response to stress, Psychother. Psychosom. 36:43.PubMedCrossRefGoogle Scholar
  69. Naber, D., Soble, M. G., and Pickar, D., 1981, Ethanol increases opioid activity in plasma of normal volunteers, Pharmakopsychiatr. Neuro-Psychopharmakol. 14:160.Google Scholar
  70. Nedopil, N., and Rüther, E., 1979, Effects of the synthetic analogue of methionine enkephalin FK 33–824 on psychotic symptoms, Pharmakopsychiatr. Neuro-Psychopharmakol. 12:277.Google Scholar
  71. Palmour, R. M., Ervin, F. R., Wagemaker, H., and Cade, R., 1979, Characterization of a peptide from the serum of psychotic patients, in: Endorphins in Mental Health Research (E. Usdin, W. E. Bunney Jr., and N. S. Kline, eds.), pp. 581–593, MacMillan Press, London.Google Scholar
  72. Pickar, D., Vartanian, F., Bunney, W. E., Jr., Maier, H. P., Gastpar, M. T., Prakash, R., Sethi, B. B., Lideman, R., Belyaev, B. S., Tsutsulkovskaja, M. V. A., Jungkunz, G., Nedopil, N., Verhoeven, W., and van Praag, H., 1982, Short-term naloxone administration in schizophrenic and manic patients, Arch. Gen. Psychiatry 39:313–319.PubMedCrossRefGoogle Scholar
  73. Pickar, D., Cutler, N. R., Naber, D., Post, R. M., Pert, C. B., and Bunney, W. E., Jr., 1980, Plasma opioid activity in manic-depressive illness, Lancet I:937.CrossRefGoogle Scholar
  74. Pickar, D., Naber, D., Post, R. M., van Kammen, D. P., Ballenger, J., Kalin, N., and Bunney, W. E., Jr., 1981, Measurement of endorphins in CSF: Relationship to psychiatric diagnosis, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 246–262, Karger, Basel.Google Scholar
  75. Rimón, R., Terenius, L., and Kampman, R., 1980, Cerebrospinal fluid endorphins in schizophrenia, Acta Psychiat. Scand. 61:395.PubMedCrossRefGoogle Scholar
  76. Ross, M., Berger, P. A., and Goldstein, A., 1979, Plasma ß-endorphin immunoreactivity in schizophrenia, Science 205:1163.PubMedCrossRefGoogle Scholar
  77. Schenk, G. K., Enders, P., Engelmeier, M. P., Ewert, T., Herdemerten, S., Köhler, K. H., Lodemann, E., Matz, D., and Pach, J., 1978, Application of the morphine antagonist naloxone in psychic disorders, Arzneim. Forsch. 28:1274.Google Scholar
  78. Snyder, S. H., 1978, The opiate receptor and morphine-like peptides in the brain, Am. J. Psychiatry 135:645.PubMedGoogle Scholar
  79. Tamminga, C. A., Tighe, P. J., Chase, T. N., De Fraites, E. G., and Schaffer, M. H., 1981, Des-tyrosine-γ-endorphin administration in chronic schizophrenics, Arch. Gen. Psychiatry 38:167.PubMedCrossRefGoogle Scholar
  80. Terenius, L., Wahlström, A., Lindström, L., and Widerlöv, E., 1976, Increased CSF levels of endorphins in chronic psychosis, Neurosci. Lett. 3:157.PubMedCrossRefGoogle Scholar
  81. Terenius, L., Wahlström, A., and Agren, H., 1977, Naloxone (Narcan®) treatment in depression: Clinical observations and effects on CSF endorphins and monoamine metabolites, Psycho-pharmacology 54:31.Google Scholar
  82. van Ree, J. M., Verhoeven, W. M. A., van Praag, H. M., and de Wied, D., 1981, Neuroleptic-like and antipsychotic effects of γ-type endorphins, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 266–278, Karger, Basel.Google Scholar
  83. Verhoeven, W. M. A., van Praag, H. M., Botter, P. A., Sunier, A., van Ree, J. M., and de Wied, D., 1978, (Des-Tyr1]-γ-endorphin in schizophrenia, Lancet I:1046.CrossRefGoogle Scholar
  84. Verhoeven, W. M. A., van Praag, H. M., van Ree, J. M., and de Wied, D., 1979, Improvement of schizophrenic patients treated with (des-Tyr1)-γ-endorphin (DT7E), Arch. Gen. Psychiatry 36:294.PubMedCrossRefGoogle Scholar
  85. Volavka, J., Mallya, A., Baig, S., and Perez-Cruet, J., 1977, Naloxone in chronic schizophrenia, Science 196:1227.PubMedCrossRefGoogle Scholar
  86. Wahlström, A., and Terenius, L., 1981, Endorphin hypothesis of schizophrenia, in: The Role of Endorphins in Neuropsychiatry (H. M. Emrich, ed.), pp. 181–191, Karger, Basel.Google Scholar
  87. Watson, S. J., Berger, P. A., Akil, H., Mills, M. J., and Barchas, J. D., 1978, Effects of naloxone on schizophrenia: Reduction in hallucinations in a subpopulation of subjects, Science 201:73.PubMedCrossRefGoogle Scholar
  88. Weygandt, W., 1935, Lehrbuch der Nerven-und Geisteskrankheiten, p. 507, Marhold-Verlagsbuchhandlung, Halle.Google Scholar

Copyright information

© Plenum Publishing Corporation 1984

Authors and Affiliations

  • H. M. Emrich
    • 1
  1. 1.Max-Planck-Institut für PsychiatrieMunichGermany

Personalised recommendations